Last Updated: 11 Sep 2024
Executive Summary
Cytosorbents Corp. (CTSO) is a critical care immunotherapy company with a market capitalization of $54.43 million. The company's blood purification technology platform incorporates proprietary adsorbent and porous polymer technology. CTSO reported a revenue of $37.16 million in the trailing twelve months (TTM), with a gross profit of $20.73 million. The company is currently unprofitable, with a TTM net income of -$22.61 million and an EPS of -$0.52.
Company Overview
Cytosorbents Corp. was founded in 2009 and is headquartered in Monmouth Junction, New Jersey. The company's products are used in the treatment of sepsis, critical illness, and cardiac surgery. CTSO's flagship product, the CytoSorb, is a blood purification device that removes toxins from the blood.
Fundamental Analysis
CTSO's financial performance has been mixed in recent years. The company reported a revenue growth of 5% in the latest quarter, but its net income declined by 10%. The company's gross profit margin is 56%, which is in line with the industry average. However, CTSO's operating margin is negative, indicating that the company is not yet profitable.
CTSO's balance sheet is relatively strong. The company has $30.5 million in cash and equivalents, and its total debt is $11.7 million. CTSO's book value is $0.308 per share.
Technical Analysis
CTSO's stock price has been trending down in recent months. The stock is currently trading at $1, which is below its 52-week high of $2.15. The stock's 50-day moving average is $1.023, and its 200-day moving average is $1.016.
Short Term Outlook
CTSO's stock price is likely to remain under pressure in the short term. The company is not yet profitable, and its revenue growth is slowing. The stock's technical indicators are also bearish, suggesting that the stock could continue to decline.
Long Term Outlook
CTSO's long-term outlook is more positive. The company's blood purification technology has the potential to be a major breakthrough in the treatment of sepsis and other critical illnesses. If CTSO can successfully commercialize its products, the company could generate significant revenue and profits.
Analyst Recommendations
The majority of analysts who cover CTSO have a "hold" rating on the stock. The average analyst target price is $4.5, which represents a potential upside of 350% from the current price.
Disclaimer
This stock market analyst report is for informational purposes only and should not be considered investment advice. Please consult with a financial advisor before making any investment decisions.
